This new measurement, researchers explained, can help clinicians target high-risk patients with more aggressive treatments. 

The SGLT2 inhibitor was approved for this new indication based on results from the EMPEROR-Reduced trial.

Aortic stenosis is only seen in 1% of younger STEMI patients, but it becomes more and more common as patients get older. 

The procedure, like the hospital's first 99 TAVR cases, was a success. 

The full Arctic Front line is now approved as a first-line treatment for heart rhythm issues. 

Moderate to severe aortic regurgitation was seen in 0.9% of patients after 30 days and 1.3% after one year.

An eight-week tai chi course provided key benefits for older stroke survivors, researchers reported. 

This was found to be true for patients taking both hydrophilic and lipophilic statins.

Frank Scholz, PhD, will oversee the Beloit, Wisconsin, firm's Mo-99 expansion efforts and new radioisotope development programs, among other duties.

The new study, published in Circulation: Cardiovascular Interventions, included data from nearly 500 TAVR patients.